CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
In recent transactions disclosed by Blueprint Medicines Corp (NASDAQ:BPMC), a $5.6 billion market cap biotechnology company, Chief Commercial Officer Lee Philina sold 3,733 shares of the company’s common stock. According to InvestingPro data, the stock has declined over 8% in the past week. The shares were sold at a price of $88.80 per share, amounting to a total transaction value of $331,490. This sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, and was not a discretionary trade by Philina. Following this transaction, Philina holds 41,996 shares directly. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.85, though analysts don’t expect profitability this year. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis for Blueprint Medicines and 1,400+ other stocks through the Pro Research Report.
In other recent news, Blueprint Medicines has made headlines with its financial and strategic developments. The company reported its fourth-quarter financials for 2024, aligning with consensus expectations, and provided revenue guidance for Ayvakit in 2025, estimating between $680 million and $710 million. This comes alongside Blueprint Medicines’ projection of achieving over $4 billion in global peak revenue for its systemic mastocytosis franchise. Analysts from Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a $150 price target, citing the potential of the company’s systemic mastocytosis franchise and the promising prospects of elenestinib and BLU-808. Meanwhile, Citizens JMP reaffirmed its Market Outperform rating with a $125 price target, emphasizing the expected sales growth of Ayvakit, projected to reach $700 million by 2025. Stifel maintained a Buy rating with a $155 price target, addressing concerns over Ayvakit’s safety, which they found to be unfounded based on their analysis. JMP Securities also held its Market Outperform rating with a $126 price target, noting the positive impact of extended follow-up data from the PIONEER trial on physician confidence in Ayvakit. These developments underscore the company’s robust pipeline and financial outlook, drawing attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.